Histamine-1 receptor antagonism for treatment of insomnia

Journal of the American Pharmacists Association

Volumn 52, Issue 6, 2012, Pages

  Vande Griend, Joseph P ^a   Anderson, Sarah L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Antihistamines; Doxepin; Histamine antagonists; Insomnia; Mirtazapine; Trazodone; Tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; ANTIHISTAMINIC AGENT; DIPHENHYDRAMINE; DOXEPIN; DOXYLAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; MIRTAZAPINE; NORTRIPTYLINE; PLACEBO; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

AROUSAL; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GROUPS BY AGE; HUMAN; INSOMNIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP; SLEEP TIME; SLEEP WAKING CYCLE;

EID: 84884779642     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2012.12051     Document Type: Article

References (51)

1. SummersMO, CrisostomoMI, StepanskiEJ. Recent developments in the classification, evaluation, and treatment of insomnia. Chest. 2006;130:276-86.
2. OhayonMM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6:97-111.
3. BhatA, ShafiF, ElSolhAA. Pharmacotherapy of insomnia. Expert Opin Pharmacother. 2008;9:351-62.
4. OzminkowskiRJ, WangS, WalshJK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep. 2007;30:263-73.
5. WalshJK, EngelhardtCL. The direct economic costs of insomnia in the United States for 1995. Sleep. 1999;22(suppl 2):S386-93.
6. StahlSM. Stahl's essential psychopharmacology. 3rd ed. New York: Cambridge University Press; 2008.
7. RameshV, ThakkarMM, StreckerRE, et al. Wakefulness-inducing effects of histamine in the basal forebrain of freely moving rats. Behav Brain Res. 2004;152:271-8.
8. StreckerRE, NalwalkJ, DauphinLJ, et al. Extracellular histamine levels in the feline preoptic/anterior hypothalamic area during natural sleep-wakefulness and prolonged wakefulness: an in vivo microdialysis study. Neuroscience. 2002;113:663-70.
9. WiegandMH. Antidepressants for the treatment of insomnia: a suitable approach? Drugs. 2008;68:2411-7.
10. StahlSM. Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008;13:1027-38.
11. MendelsonWB, RothT, CassellaJ, et al. The treatment of chronic insomnia: drug indications, chronic use and abuse liability: summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med Rev. 2004;8:7-17.
12. Schutte-RodinS, BrochL, BuysseD, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008;4:487-504.
13. MorinCM, KoetterU, BastienC, et al. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep. 2005;28:1465-71.
14. GlassJR, SprouleBA, HerrmannN, et al. Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial. J Clin Psychopharmacol. 2008;28:182-8.
15. RickelsK, MorrisRJ, NewmanH, et al. Diphenhydramine in insomniac family practice patients: a double-blind study. J Clin Pharmacol. 1983;23:234-42.
16. MeulemanJR, NelsonRC, ClarkRL Jr. Evaluation of temazepam and diphenhydramine as hypnotics in a nursing-home population. Drug Intell Clin Pharm. 1987;21:716-20.
17. SjoqvistF, LasagnaL. The hypnotic efficacy of doxylamine. Clin Pharmacol Ther. 1967;8:48-54.
18. WinokurA, SateiaMJ, HayesJB, et al. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry. 2000;48:75-8.
19. WinokurA, DeMartinisNA 3rd, McNallyDP, et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry. 2003;64:1224-9.
20. CankurtaranES, OzalpE, SoygurH, et al. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer. 2008;16:1291-8.
21. KimSW, ShinIS, KimJM, et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci. 2008;62:75-83.
22. RadhakishunFS, van den BosJ, van der HeijdenBC, et al. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol. 2000;20:531-7.
23. RuigtGS, KempB, GroenhoutCM, et al. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol. 1990;38:551-4.
24. ShenJ, ChungSA, KayumovL, et al. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry. 2006;51:27-34.
25. SchittecatteM, DumontF, MachowskiR, et al. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology. 2002;46:197-201.
26. AsianS, IsikE, CosarB. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep. 2002;25:677-9.
27. LeBonO, MurphyJR, StanerL, et al. Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. J Clin Psychopharmacol. 2003;23:377-83.
28. WalshJK, ErmanM, ErwinCW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Human Psychopharmacol. 1998;13:191-8.
29. RothAJ, McCallWV, LiguoriA. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res. 2011;20:552-8.
30. SteinMD, KurthME, SharkeyKM, et al. Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011;120:65-73.
31. RiemannD, VoderholzerU, CohrsS, et al. Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry. 2002;35:165-74.
32. HajakG, RodenbeckA, VoderholzerU, et al. Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry. 2001;62:453-63.
33. RothT, RogowskiR, HullS, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. 2007;30:1555-61.
34. ScharfM, RogowskiR, HullS, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2008;69:1557-64.
35. KrystalAD, DurrenceHH, ScharfM, et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep. 2010;33:1553-61.
36. RothT, HeithDurrenceH, JochelsonP, et al. Efficacy and safety of doxepin 6 mg in a model of transient insomnia. Sleep Med. 2010;11:843-7.
37. KrystalAD, LankfordA, DurrenceHH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011;34:1433-42.
38. LankfordA, RogowskiR, EssinkB, et al. Efficacy and safety of doxepin 6mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med. 2011;13:133-8.
39. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616-31.
40. Micromedex Healthcare Series. Doxepin, diphenhydramine, and trazodone. Accessed at www.thomsonhc.com/home/dispatch, March 5, 2012.
41. SchweitzerPK, MuehlbachMJ, WalshJK. Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J Allergy Clin Immunol. 1994;94:716-24.
42. ManningC, ScandaleL, ManningEJ, GengoFM. Central nervous system effects of meclizine and dimenhydrinate: evidence of acute tolerance to antihistamines. J Clin Pharmacol. 1992;32:996-1002.
43. ByeCE, ClaridgeR, PeckAW, PlowmanF. Evidence for tolerance to the central nervous effects of the histamine antagonist, triprolidine, in man. Eur J Clin Pharmacol. 1977;12:181-6.
44. LevanderS, Stahle-BackdahlM, HagermarkO. Peripheral antihistamine and central sedative effects of single and continuous oral doses of cetirizine and hydroxyzine. Eur J Clin Pharmacol. 1991;41:435-9.
45. MontiJM, MontiD. Histamine H1 receptor antagonists in the treatment of insomnia: is there a rational basis for use? CNS Drugs. 2000;13:87-96.
46. StimmelGL, DopheideJA, StahlSM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy. 1997;17:10-21.
47. ThaseME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry. 1999;60(suppl 17):28-31.
48. FoxCB, TreadwayAK, BlaszczykAT, SleeperRB. Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly. Pharmacotherapy. 2009;29:383-97.
49. RoyAN, SmithM. Prevalence and cost of insomnia in a state Medicaid fee-for-service population based on diagnostic codes and prescription utilization. Sleep Med. 2010;11:462-9.
50. MendelsonWB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66:469-76.
51. BuscemiN, VandermeerB, FriesenC, BialyL. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007;22:1335-50.